PharmaMar Announces That Its Phase I Study on Japanese Patients With Lurbinectedin in Monotherapy Has Achieved Its Objective

• This study aimed to determine the appropriate dose for Japanese patients treated with lurbinectedin, in monotherapy, for advanced solid tumors.
• The recommended dose is 3.2 mg/m² with the use of colony stimulating factors.

Madrid, August 27^th, 2019.- PharmaMar (MSE:PHM) today announced that its Phase I study to determine the dose in Japanese patients on lurbinectedin monotherapy for advanced solid tumors has achieved its objective. The recommended dose is 3.2 mg/m² - the same as in Western patients - using colony-stimulating factors.

In this study, which was carried out in 3 hospitals in Japan, 26 patients have been treated and their recruitment ended in May 2019.

In the words of Luis Mora, General Manager of the Oncology Business Unit: “Getting the same recommended dose of treatment in Japanese patients as in Westerners is very important, as it simplifies the clinical development of the drug in Japan and makes it much more attractive for a possible license in that territory.”

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis^® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director

investorrelations@pharmamar.com

Phone: +34 914444500